We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Rejects Additional Indication for Eisai’s Dacogen in AML
FDA Rejects Additional Indication for Eisai’s Dacogen in AML
March 9, 2012
The FDA has rebuffed an sNDA for Eisai’s oncologic Dacogen after it failed to show superiority in treating acute myelogenous leukemia (AML) patients age 65 and older.